|
| Scientific Program |
| |
|
| Scientific Program | Search Abstract |
| |
|
|
| Session |
| |
| Acute myeloid leukemia - Clinical II |
| Date: |
Saturday, 06 June 2009
|
| Time: | 18:00-19:15 |
| Room: | |
| |
| 18:00-19:15 |
|
COMBINATION OF IDARUBICIN, HIGH DOSE CYTARABINE AND SORAFENIB IS HIGHLY EFFECTIVE IN ACHIEVING REMISSION IN NEWLY DIAGNOSED, FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML)
| 0831 |
| Ravandi, Farhad,
Andreeff, Michael,
Garcia-Manero, Guillermo,
Faderl, Stefan,
Konopleva, Marina,
O'Brien, Susan,
Byrd, Anna,
Brandt, Mark,
Zhang, Weiguo,
Jones, Dan,
Levis, Mark,
Cortes, Jorge,
Kantarjian, Hagop
(Houston, United States of America) |
| |
| 18:00-19:15 |
|
IMPROVED OUTCOME BY ADDITION OF LOMUSTINE (CCNU) TO IDARUBICIN AND CYTARABINE IN ELDERLY PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA. A REPORT FROM THE GOELAMS GROUP
| 0832 |
| Pigneux, Arnaud,
Harousseau, J.l.,
Witz, F.,
Sauvezie, M.,
Bene, M.C.,
Luquet, I.,
Leguay, T.,
Hunault-berger, M.,
Recher, C.,
Vey, N.,
Lioure, B.,
Himberlin, C.,
Dreyfus, F.,
Reiffers, J.,
Milpied, N.,
Ifrah, N.
(Pessac, France) |
| |
| 18:00-19:15 |
|
PROLONGED EXPOSURE TO LINTUZUMAB MONOTHERAPY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES – RESULTS OF A PHASE 1 TRIAL
| 0833 |
| Raza, Azra,
Jurcic, Joseph G.,
Feldman, Eric J.,
Maris, Michael,
Stephenson, Joseph,
Frankel, Arthur E.,
Cooper, Maureen,
Wade, James,
Wood, Brent L.,
Galili, Naomi,
Siadak, Muriel,
Sievers, Eric L.,
Drachman, Jonathan G.,
Roboz, Gail J.
(New York, United States of America) |
| |
| 18:00-19:15 |
|
AS1411 IN COMBINATION WITH CYTARABINE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
| 0834 |
| Stuart, Robert,
Stockerl-Goldstein, K.,
Cooper, M.,
Devetten, M.,
Herzig, R.,
Medeiros, B.,
Schiller, G.,
Wei, A.,
Acton, G.,
Rizzieri, D.
(Charleston, United States of America) |
| |
| 18:00-19:15 |
|
CLASSIC II: UPDATED REMISSION DURATION AND SURVIVAL RESULTS OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AND AT LEAST ONE UNFAVORABLE BASELINE PROGNOSTIC FACTOR
| 0835 |
| Kantarjian, Hagop,
Erba, Harry,
Claxton, David,
Arellano, Martha,
Lyons, Roger,
Kovacsovics, Tibor,
Gabrilove, Janice,
Eckert, Stephen,
Faderl, Stefan
(Texas, United States of America) |
| |
| 18:00-19:15 |
|
PROGNOSIS OF PATIENTS WITH AML CARRYING 11Q23/MLL RECIPROCAL TRANSLOCATIONS : A RETROSPECTIVE STUDY OF 191 CASES FROM THE FRENCH AML-INTERGROUP
| 0836 |
| Banos, Anne,
Jaquet, Antoine,
Auvrignon, Anne,
Dastugue, Nicole,
Castaigne, Sylvie,
Michel, Gérard,
Fenaux, Pierre,
Recher, Christian,
Reiffers, Josy,
Socié, Gérard,
Harousseau, Jean-Luc,
Blaise, Didier,
Lioure, Bruno,
Bastard, christian,
Ifrah, Norbert,
Dombret, Hervé,
Pigneux, Arnaud
(Bayonne, France) |
| |
| 18:00-19:15 |
|
IMPROVED OUTCOME WITH ANDROGENS AS MAINTENANCE TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AFTER ICL REGIMEN AS INDUCTION THERAPY: RESULTS OF THE GOELAMS SA-2002 MULTICENTER PHASE III RANDOMIZED OPEN TRIAL
| 0837 |
| Pigneux, Arnaud,
Himberlin, C.,
Hunault-berger, M.,
Witz, F.,
Leguay, T.,
Recher, C.,
Harousseau, J.l.,
Lioure, B.,
Milpied, N.,
Luquet, I.,
Bene, M.C.,
Ifrah, N.,
Dreyfus, F.,
Perry, F.,
Sotto, J.,
Guardiola, P.
(Pessac, France) |
| |
| 18:00-19:15 |
|
THE COMBINATION OF FLOW-CYTOMETRY MINIMAL RESIDUAL DISEASE ASSESSMENT AND CYTOGENETIC/GENETIC PARAMETERS ALLOWS A PROPER RISK STRATIFICATION OF ADULT AML PATIENTS: IMPLICATION FOR TRANSPLANT CHOICE AND POST CONSOLIDATION THERAPY
| 0838 |
| Buccisano, Francesco,
Maurillo, Luca,
Del Principe, Maria Ilaria,
Del Poeta, Giovanni,
Irno Consalvo, Maria Antonietta,
Fraboni, Daniela,
Lavorgna, Serena,
Ottone, Tiziana,
Campagna, Selenia,
Ammatuna, Emanuele,
Rizzo, Manuela,
Giannì, Laura,
Postorino, Massimiliano,
Arcese, William,
Lo Coco, Francesco,
Amadori, Sergio,
Venditti, Adriano
(Rome, Italy) |
| |
| 18:00-19:15 |
|
PROGNOSTIC AND PREDICTIVE FACTORS FOR SURVIVAL AFTER COMPLETE REMISSION IN INDUCTION THERAPY OF ACUTE MYELOID LEUKAEMIA
| 0839 |
| Pfirrmann, Markus,
Soucek, Silke ,
Bornhaeuser, Martin,
Illmer, Thomas,
Ehninger, Gerhard,
Schaich, Markus
(Munich, Germany) |
| |
| 18:00-19:15 |
|
AMONAFIDE (AS1413) IS UNAFFECTED BY MULTIDRUG RESISTANCE AND IS ASSOCIATED WITH A HIGH RESPONSE RATE IN PATIENTS WITH SECONDARY AML
| 0840 |
| Lundberg, Ante,
Chau, MyDoanh,
Erba, Harry,
Dressel, Amanda,
Acton, Gary,
Capizzi, Robert,
Baer, Maria
(Cambridge, United States of America) |
| |
| 18:00-19:15 |
|
PRE- AND POST-TRANSPLANT FACTORS PREDICT LONG TERM SURVIVAL AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKAEMIA
| 0841 |
| Craddock, Charles,
Nagra, Sandeep,
Duncan, Nick,
Mackinnon, Stephen,
Russell, Nigel
(Birmingham, United Kingdom) |
| |
| 18:00-19:15 |
|
MLN8237, A NOVEL ORALLY ACTIVE AURORA A KINASE INHIBITOR, IS HIGHLY ACTIVE ALONE AND IN COMBINATION WITH CYTARABINE IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
| 0842 |
| Kelly, Kevin,
Swords, Ronan,
Mahalingam, Devalingam,
Nawrocki, Steffan,
Medina, Ernest,
Smith, Sabrina,
Padmanabhan, Swaminathan,
Ecsedy, Jeffrey,
Giles, Francis J.,
Carew, Jennifer
(San Antonio, United States of America) |
| |
| 18:00-19:15 |
|
IMPACT OF MYELODYSPLASIA-RELATED CHANGES AS DEFINED BY THE 2008 WHO CLASSIFICATION SYSTEM IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED INTENSIVELY
| 0843 |
| Gardin, Claude,
Terré , Christine,
Gachard, Nathalie,
Tigaud, Isabelle,
Desangles, Francois,
Bastard, Christian,
Maarek, Odile,
Lai, Jean-Luc,
Bernheim, Alain,
Perot, Christine,
Eclache, Virginie,
Turlure, Pascal,
Thomas, Xavier,
Castaigne, Sylvie,
Michallet, Mauricette,
Preudhomme, Claude,
Fagot, Thierry,
Bordessoule, Dominique,
Fenaux, Pierre,
Dombret, Herve
(Bobigny, France) |
| |
| 18:00-19:15 |
|
FLUDARABINE-BASED INDUCTION THERAPY DOES NOT OVERCOME THE NEGATIVE EFFECT OF ABCG2 (BCRP) OVER-EXPRESSION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS
| 0844 |
| Tiribelli, Mario,
Geromin, Antonella,
Michelutti, Angela,
Cavallin, Margherita,
Candoni, Anna,
Toffoletti, Eleonora,
Fanin, Renato,
Damiani, Daniela
(Udine, Italy) |
| |
| 18:00-19:15 |
|
SIX-YEAR OUTCOMES UPDATE FROM A RANDOMIZED PHASE 3 TRIAL
IN AML: DURABLE EFFECT OF REMISSION MAINTENANCE IMMUNOTHERAPY WITH HISTAMINE DIHYDROCHLORIDE AND LOW-DOSE IL-2
| 0845 |
| Brune, Mats,
Rowe, Jacob M.,
Buyse, Marc E.,
Squifflet, Pierre,
Castaigne, Sylvie,
Allard, Stephane E.,
Hellstrand, Kristoffer (P)
(Gothenburg, Sweden) |
| |
| 18:00-19:15 |
|
CXCR4 AS A PREDICTOR OF RESPONSE IN ACUTE MYELOID LEUKAEMIA
| 0846 |
| Giannoccaro, Margherita,
Mestice, A,
Pastore, D,
Liso, A,
Longo, MC,
Fesce, V,
Ingrosso, C,
Sgherza, N,
Manduzio, P,
Mongelli, P,
Angarano, R,
Mazzone, A,
Liso, V,
Specchia , G
(Bari, Italy) |
| |
| 18:00-19:15 |
|
RASGRP1/APTX RATIO STRONGLY CORRELATES WITH CLINICAL RESPONSE AND SURVIVAL IN AML PATIENTS TREATED WITH TIPIFARNIB-BORTEZOMIB COMBINATION
| 0847 |
| Paolini, Stefania,
Ottaviani, Emanuela,
Lama, Barbara,
Salmi, Federica,
Parisi, Sarah,
Clissa, Cristina,
Curti, Antonio,
Finelli, Carlo,
Iacobucci, Ilaria,
Laterza, Claudio,
Papayannidis, Cristina,
Piccaluga, Pier Paolo,
Vianelli, Nicola,
Saglio, Giuseppe,
Fanin, Renato,
Morabito, Fortunato,
Zaccaria, Alfonso,
Lauria, Francesco,
Gobbi, Marco,
Amadori, Dino,
Baccarani, Michele,
Martinelli, Giovanni
(Bologna, Italy) |
| |
| 18:00-19:15 |
|
IMPACT OF MOLECULAR MARKERS AND CYTOGENETIC ABNORMALITIES ON LONG-TERM OVERALL SURVIVAL AND DISEASE FREE SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS (HSCT)
| 0848 |
| Michallet, Mauricette,
Sobh, Mohamad,
Barraco, Fiorenza,
Nicolini, Franck,
Dumontet, Charles,
Chelghoum, Youcef,
Cannas, Giovanna,
Nicolas-Virelizier, Emmanuelle,
Plesa, Nicolae,
Ducastelle, Sophie,
Troncy, Jacques,
Thomas, Xavier
(Lyon, France) |
| |
| 18:00-19:15 |
|
PHASE 1B/2 PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) STUDY OF COMBINATION VORELOXIN AND CYTARABINE IN RELAPSED OR REFRACTORY AML PATIENTS
| 0849 |
| Lancet, Jeffrey,
Roboz, Gail,
Cripe, Larry,
Karp, Judith,
Berman, Craig,
Hawtin, Rachael,
Chen, Tianling,
Fox, Judith,
Michelson, Glenn
(Tampa, United States of America) |
| |
| 18:00-19:15 |
|
THE SAFETY AND EFFICACY OF AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED AND REFRACTORY/RELAPSED AML NOT ELIGIBLE FOR OR RESISTANT TO CHEMOTHERAPY: A MULTI-CENTER PHASE I/II-STUDY OF THE EAST GERMAN HAEMATOLOGY AND ONCOLOGY STUDY GROUP (OSHO)
| 0850 |
| Al-Ali, Haifa Kathrin
(Leipzig, Germany) |
| |
|